Drug Profile
LY 900009
Alternative Names: LY900009Latest Information Update: 26 Oct 2012
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors; Angiogenesis inhibitors; Apoptosis stimulants; Notch signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Oct 2012 Discontinued - Phase-I for Cancer in USA (PO)
- 31 Aug 2012 Eli Lilly completes a phase I trial in Cancer in USA (NCT01158404)
- 20 Jul 2010 Phase-I clinical trials in Cancer in USA (PO)